I definitely do, and in my statement that's what I was trying to get to. The imperatives here for the few multinational corporations that are dominating the market right now, as we can see in the COVID pandemic, are monopolizing and restricting the global production capacity.
Right now there is an opportunity for the global community to say that this is the moment when we can challenge the status quo and make the global network a place where IP rights being waived is not the only solution. The companies do need to share know-how, intellectual property and data with other qualified vaccine manufacturers. There needs to be a strengthening of regulatory capacity, and there needs to be an investment in local vaccine manufacturing.
As I was saying in March, over the last few decades there has been this deterioration of that regulatory capacity and local investment. It is a long-term game, but right now we're in extraordinary circumstances and there's no better time to take extraordinary measures.
The last speaker said we're so far off from being able to consider this, but I would say that now is the time. Sure, there are a lot of other barriers and complexities to it. That is why we need to be talking about it right now.
I hope that answers the question.